TD ADSORBED SUSPENSION
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
12-07-2022
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
TETANUS TOXOID ADSORBED; DIPHTHERIA TOXOID ADSORBED
Available from:
SANOFI PASTEUR LIMITED
ATC code:
J07AM51
INN (International Name):
TETANUS TOXOID, COMB. WITH DIPHTHERIA TOXOID
Dosage:
5LF; 2LF
Pharmaceutical form:
SUSPENSION
Composition:
TETANUS TOXOID ADSORBED 5LF; DIPHTHERIA TOXOID ADSORBED 2LF
Administration route:
INTRAMUSCULAR
Units in package:
100
Prescription type:
Schedule D
Product summary:
Active ingredient group (AIG) number: 0214427001; AHFS:
Authorization status:
APPROVED
Authorization date:
2022-06-27
Summary of Product characteristics
SANOFI PASTEUR PRODUCT MONOGRAPH
384, 420 TD ADSORBED
_Td ADSORBED (Tetanus and Diphtheria Toxoids Adsorbed) Page 1 of 22 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
TD ADSORBED
TETANUS AND DIPHTHERIA TOXOIDS ADSORBED
Each 0.5 mL dose contains 5 Lf of Tetanus Toxoid and 2 Lf of
Diphtheria Toxoid
Suspension for injection
(For active immunization against Tetanus and Diphtheria)
ATC Code: J07AM51
SANOFI PASTEUR LIMITED
Toronto, Ontario, Canada
Date of Initial Authorization:
JUL 09, 1980
Date of Revision:
JUL 12, 2022
SUBMISSION CONTROL NUMBER: 261425
SANOFI PASTEUR PRODUCT MONOGRAPH
384, 420 TD ADSORBED
_Td ADSORBED (Tetanus and Diphtheria Toxoids Adsorbed) Page 2 of 22 _
TABLE OF CONTENTS
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
................................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics.............................................................................................................4
2
CONTRAINDICATIONS
...................................................................................................4
4
DOSAGE AND
ADMINISTRATION...................................................................................4
4.2
Recommended Dose and Dosage
Adjustment.......................................................4
4.4
Administration.....................................................................................................6
5
OVERDOSAGE
...............................................................................................................6
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
...................................6
7
WARNINGS AND PRECAUTIONS
................
Read the complete document
